Markets

First Tracks Biotherapeutics Announces ~$200M Private Placement Of 6,106,870 Shares At $32.75/Share To Institutional Investors

Oct 15, 2026 · 08:02 AM ET· updated 1h ago

First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced

Why It Matters

First Tracks raised about $200 million by selling new shares to big investors. When a company does this, watch if they use the money wisely on their medicine research.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

TRAX35.42

+1.29 (+3.78%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.